Thromboxane in Ischemic Heart Disease

Robert Ira Lewy, Edwin W. Salzman, Michael Sobel, Allan B. Zelinger, Edgar C. Schick, Thomas J. Ryan, Andrzej Zalewski, Paul D. Hirsh, L. David Hillis, William B. Campbell, Brian G. Firth, James T. Willerson

Research output: Contribution to journalLetter

2 Scopus citations

Abstract

To the Editor: The report by Hirsh et al. in the March 19 issue,1 in which increased levels of coronary-sinus thromboxane B2 were demonstrated in patients with recent episodes of angina, supports previous experimental data showing increased thromboxane B2 levels in coronary-sinus blood of patients with exercise-induced angina2 and of patients with fixed obstructive coronary-artery disease in whom angina was induced by rapid atrial pacing.3 It is of broader potential importance that levels of thromboxane B2 in peripheral blood have been shown by several investigators to rise acutely during chest pain in patients known to have coronary-artery. . .

Original languageEnglish (US)
Pages (from-to)106-107
Number of pages2
JournalNew England Journal of Medicine
Volume305
Issue number2
DOIs
StatePublished - Jul 9 1981

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Thromboxane in Ischemic Heart Disease'. Together they form a unique fingerprint.

  • Cite this

    Lewy, R. I., Salzman, E. W., Sobel, M., Zelinger, A. B., Schick, E. C., Ryan, T. J., Zalewski, A., Hirsh, P. D., Hillis, L. D., Campbell, W. B., Firth, B. G., & Willerson, J. T. (1981). Thromboxane in Ischemic Heart Disease. New England Journal of Medicine, 305(2), 106-107. https://doi.org/10.1056/NEJM198107093050219